Due to increased life expectancy and lifestyle changes, the prevalence of diabetes among the elderly in Korea is continuously rising, as is the associated public health burden. Diabetes management in elderly patients is complicated by age-related physiological changes, sarcopenia characterized by loss of muscle mass and function, comorbidities, and varying levels of functional, cognitive, and mobility abilities that lead to frailty. Moreover, elderly patients with diabetes frequently face multiple chronic conditions that elevate their risk of cardiovascular diseases, cancer, and mortality; they are also prone to complications such as hyperglycemic hyperosmolar state, diabetic ketoacidosis, and severe hypoglycemia. This review examines the characteristics of and management approaches for diabetes in the elderly, and advocates for a comprehensive yet personalized strategy.
Citations
Citations to this article as recorded by
Diabetes Fact Sheets in Korea 2024 Se Eun Park, Seung-Hyun Ko, Ji Yoon Kim, Kyuho Kim, Joon Ho Moon, Nam Hoon Kim, Kyung Do Han, Sung Hee Choi, Bong Soo Cha Diabetes & Metabolism Journal.2025; 49(1): 24. CrossRef
The effect of multidisciplinary team and experience-based co-design on the care of older adult patients with type 2 diabetes: A randomized controlled trial Yujun Zhuang, Hongjiang Ye, Xiaoyan Yang, Lifang Zheng, Zhizhen Chen, Jianjia Jiang, Lunpan Mou, Pingping Li, Jiawei Qin, Yaduan Dai, Yanling Mao Diabetes Research and Clinical Practice.2025; 221: 112028. CrossRef
The national healthcare systems of every country in the world cannot sustain the rise in healthcare expenditure caused by chronic diseases and their complications. To sustain the national healthcare system, a novel system should be developed to improve the quality of care and minimize healthcare costs. For 20 years, our team developed patient-communicating digital healthcare platforms and proved their efficacy. National scale randomized control trials are underway to systematically measure the efficacy and economic benefits of this digital health care system. Precision medicine aims to maximize effectiveness of disease management by considering individual variability. Digital health technologies enable precision medicine at a reasonable cost that was not available before. The government launched the “National Integrated Bio-big Data Project” which will collect diverse health data from the participants. Individuals will share their health information to physicians or researchers at their will by gateway named “My-Healthway.’ Taken together, now we stand in front of the evolution of medical care, so-called “Precision medicine.” led by various kinds of technologies and a huge amount of health information exchange. We should lead these new trends as pioneers, not as followers, to establish and implement the best care for our patients that can help them to withstand their devastating diseases.
Citations
Citations to this article as recorded by
Technological Innovations Transforming Diabetes Care in Practice Shinae Kang The Journal of Korean Diabetes.2024; 25(2): 57. CrossRef
Islet transplantation in Korea Joonyub Lee, Kun‐Ho Yoon Journal of Diabetes Investigation.2024; 15(9): 1165. CrossRef
The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents—obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol—are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.
Citations
Citations to this article as recorded by
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan Biomolecules.2025; 15(1): 140. CrossRef
Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin Current Drug Therapy.2024; 19(1): 20. CrossRef
Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review Pervej Alom Barbhuiya, Saikat Sen, Manash Pratim Pathak Phytochemistry Reviews.2024; 23(4): 969. CrossRef
Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection Shibing Tao, Shanlan Guo, Nanwei Tong Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2024; 44(8): 642. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee Metabolism.2023; 145: 155612. CrossRef
Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study Willy B Theel, Bianca M Boxma-de Klerk, Femme Dirksmeier-Harinck, Elisabeth FC van Rossum, Danny A Kanhai, Jan A Apers, Bas M van Dalen, Robert J De Knegt, Bojou Neecke, Ellen M van der Zwan, Diederick E Grobbee, Thomas Hankemeier, Janneke Wiebolt, Manuel BMJ Open.2023; 13(7): e070431. CrossRef
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies Youngmin A. Lee, Scott L. Friedman Journal of Internal Medicine.2022; 291(1): 11. CrossRef
Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial Eugene Han, Ji Hye Huh, Eun Y. Lee, Ji C. Bae, Sung W. Chun, Sung H. Yu, Soo H. Kwak, Kyong S. Park, Byung‐Wan Lee Diabetes, Obesity and Metabolism.2022; 24(4): 752. CrossRef
Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park Obesity.2022; 30(6): 1279. CrossRef
Thyroid diseases and new approaches for their treatment E. A. Fokina, A. O. Shpakov The Siberian Journal of Clinical and Experimental Medicine.2022; 37(3): 90. CrossRef
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction Giang Nguyen, So Young Park, Dinh Vinh Do, Dae-Hee Choi, Eun-Hee Cho Endocrinology and Metabolism.2022; 37(6): 918. CrossRef
Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH Su-Yeon Lee, Sanghwa Kim, Inhee Choi, Yeonhwa Song, Namjeong Kim, Hyung Chul Ryu, Jee Woong Lim, Hyo Jin Kang, Jason Kim, Haeng Ran Seo Cell Death & Disease.2022;[Epub] CrossRef
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan International Journal of Molecular Sciences.2022; 24(1): 158. CrossRef
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC Hyunmi Kim, Da Som Lee, Tae Hyeon An, Hyun-Ju Park, Won Kon Kim, Kwang-Hee Bae, Kyoung-Jin Oh International Journal of Molecular Sciences.2021; 22(9): 4495. CrossRef
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong Scientific Reports.2021;[Epub] CrossRef
Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis João Remí de Freitas Júnior, Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Vitor Massaro Takamatsu Sagae, Gabriel Mayo Vieira de Souza, Guilherme Henrique Peixoto de Oliveira, Sergio A Sánchez-Luna, Thiago Ferreira de Souza, Eduardo Turiani Hourne World Journal of Hepatology.2021; 13(7): 815. CrossRef
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease Branka Filipovic, Snezana Lukic, Dragana Mijac, Marija Marjanovic-Haljilji, Marko Vojnovic, Jelena Bogdanovic, Tijana Glisic, Natasa Filipovic, Jamal Al Kiswani, Aleksandra Djokovic, Suncica Kapor, Slobodan Kapor, Zoran Bukumiric, Ana Starcevic International Journal of Molecular Sciences.2021; 22(24): 13219. CrossRef